Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMU-838 in progressive multiple sclerosis
NL-OMON54447Phase 2Recruiting
- Sponsor
- Immunic Therapeutics
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of vidofludimus calcium in multiple sclerosis (MS), primary progressive multiple sclerosis (PPMS) and secondary-progressive multiple sclerosis (SPMS) (3 arms), sponsored by Immunic Therapeutics. Primary endpoint: Annualized rate of percent brain volume change during main treatment period. Started Jul 2022; status: recruiting.
02
Drugs
vidofludimus calcium
03
Conditions
multiple sclerosis (MS)primary progressive multiple sclerosis (PPMS)secondary-progressive multiple sclerosis (SPMS)
Beyond the preview
Go deeper on NL-OMON54447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54447.